Back

Treatment with macitentan for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): Real-world experience from the combined OPUS and OrPHeUS data sets

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters Pulmonary Hypertension ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Vallerie McLaughlin

University of Michigan, Ann Arbor (United States of America)

62 More presentations in this session

Presentation thumbnail
Shift in transcriptional landscape of human right ventricle in chronic thromboembolic pulmonary arterial hypertension
Ms L. Jafari (Giessen, DE)
Abstract Slides
Presentation thumbnail
Relationship between right ventricular diastolic dysfunction, right atrial phasic function and ventricular filling in pulmonary arterial hypertension
Mr J. Wessels (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Aetiology of sarcoidosis-associated pulmonary hypertension
Mr H. Mathijssen (Nieuwegein, NL)
Abstract Slides
Presentation thumbnail
Pre-operative pulmonary artery pulsatility index does not predict mortality post cardiac transplantation but PVR is a prognostic tool in LVAD-bridged patients.
Doctor N. Bart (Boston, US)
Abstract Slides
Presentation thumbnail
Venous lactate predicts adverse outcomes in normotensive pulmonary embolism
Doctor M. Ebner (Berlin, DE)
Abstract Slides

Access the full session

Session thumbnail
Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)
28 August 2022
thumbnail
Congress Presentation
Oral anticoagulation in 13,344 adult patients with congenital heart disease (ACHD) in a longitudinal real-world setting in 2005-2017
2 September 2019
thumbnail
Webinar
What's new in the diagnosis and treatment of pulmonary hypertension, Part 2. Understanding specific aspects of congenital heart disease, chronic thromboembolic PH, and the patient's voice
20 December 2022
thumbnail
Congress Presentation
Risk assessment tool implementation in congenital heart disease associated pulmonary arterial hypertension
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources